Christie E Tung1, Sandra S Win, Maarten G Lansberg. 1. Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305-5235, USA. cetung@stanford.edu
Abstract
BACKGROUND AND PURPOSE: The aim of this study was to determine the cost-effectiveness of tissue-type plasminogen activator (tPA) treatment in the 3- to 4.5-hour time window after ischemic stroke. METHODS: Decision-analytic and Markov state-transition models were created to determine the cost-effectiveness of treatment of ischemic stroke patients with intravenous tPA administered in the 3- to 4.5-hour time window compared with medical therapy without tPA. Health benefits were measured in quality-adjusted life-years (QALYs). The economic outcome measure of the model was the difference in estimated healthcare costs between the 2 treatment alternatives. The incremental cost-effectiveness ratio was calculated by dividing the cost difference by the difference in QALYs. One-way sensitivity and probabilistic analyses were performed to test the robustness of the model. RESULTS: The administration of tPA compared with standard medical therapy resulted in a lifetime gain of 0.28 QALYs for an additional cost of $6050, yielding an incremental cost-effectiveness ratio of $21 978 per QALY. One-way sensitivity analyses demonstrated that the incremental cost-effectiveness ratio was most sensitive to the cost of hospitalization for patients who received tPA. Based on probabilistic analysis, there is an 88% probability that tPA is the preferred treatment at a willingness-to-pay threshold of $50 000 per QALY. CONCLUSIONS: The balance of costs and benefits favors treatment with intravenous tPA in the 3- to 4.5-hour time window. This supports, from a societal perspective, the use of tPA therapy in this treatment time window for acute ischemic stroke.
BACKGROUND AND PURPOSE: The aim of this study was to determine the cost-effectiveness of tissue-type plasminogen activator (tPA) treatment in the 3- to 4.5-hour time window after ischemic stroke. METHODS: Decision-analytic and Markov state-transition models were created to determine the cost-effectiveness of treatment of ischemic strokepatients with intravenous tPA administered in the 3- to 4.5-hour time window compared with medical therapy without tPA. Health benefits were measured in quality-adjusted life-years (QALYs). The economic outcome measure of the model was the difference in estimated healthcare costs between the 2 treatment alternatives. The incremental cost-effectiveness ratio was calculated by dividing the cost difference by the difference in QALYs. One-way sensitivity and probabilistic analyses were performed to test the robustness of the model. RESULTS: The administration of tPA compared with standard medical therapy resulted in a lifetime gain of 0.28 QALYs for an additional cost of $6050, yielding an incremental cost-effectiveness ratio of $21 978 per QALY. One-way sensitivity analyses demonstrated that the incremental cost-effectiveness ratio was most sensitive to the cost of hospitalization for patients who received tPA. Based on probabilistic analysis, there is an 88% probability that tPA is the preferred treatment at a willingness-to-pay threshold of $50 000 per QALY. CONCLUSIONS: The balance of costs and benefits favors treatment with intravenous tPA in the 3- to 4.5-hour time window. This supports, from a societal perspective, the use of tPA therapy in this treatment time window for acute ischemic stroke.
Authors: S C Fagan; L B Morgenstern; A Petitta; R E Ward; B C Tilley; J R Marler; S R Levine; J P Broderick; T G Kwiatkowski; M Frankel; T G Brott; M D Walker Journal: Neurology Date: 1998-04 Impact factor: 9.910
Authors: G P Samsa; R A Reutter; G Parmigiani; M Ancukiewicz; P Abrahamse; J Lipscomb; D B Matchar Journal: J Clin Epidemiol Date: 1999-03 Impact factor: 6.437
Authors: J A Hirsch; A J Yoo; R G Nogueira; L A Verduzco; L H Schwamm; J C Pryor; J D Rabinov; R G González Journal: J Neurointerv Surg Date: 2009-07-03 Impact factor: 5.836
Authors: Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni Journal: N Engl J Med Date: 2008-09-25 Impact factor: 91.245
Authors: Silke Walter; Iris Q Grunwald; Stefan A Helwig; Andreas Ragoschke-Schumm; Michael Kettner; Mathias Fousse; Martin Lesmeister; Klaus Fassbender Journal: Curr Atheroscler Rep Date: 2018-08-29 Impact factor: 5.113
Authors: Denise M Boudreau; Greg Guzauskas; Kathleen F Villa; Susan C Fagan; David L Veenstra Journal: Ann Emerg Med Date: 2012-05-24 Impact factor: 5.721